Latest news

Today, 11:28 PM

JP Morgan analyst Jeffrey Zekauskas downgrades Corteva (NYSE:CTVA) from Overweight to Neutral.

1 minute read

Keybanc Maintains Overweight on Corteva, Raises Price Target to $64

Today, 11:28 PM

Keybanc analyst Aleksey Yefremov maintains Corteva (NYSE:CTVA) with a Overweight and raises the price target from $63 to $64.

27 minute read

Earnings Scheduled For May 4, 2022

Today, 11:28 PM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

2 minute read

Traders Moved These 13 Stocks On Tuesday’s CNBC’s ‘Fast Money: Halftime Report’

By AJ Fabino

Today, 11:28 PM

CNBC’s ‘Fast Money: Halftime Report’ delivers market-moving news to investors.

BABA

1 minute read

Analyst Ratings

Where Corteva Stands With Analysts

Today, 11:28 PM

Within the last quarter, Corteva (NYSE:CTVA) has observed the following analyst ratings:

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 14, 2022

Today, 11:28 PM

Upgrades

ADYEY

1 minute read

Keybanc Maintains Overweight on Corteva, Raises Price Target to $63

Today, 11:28 PM

Keybanc maintains Corteva (NYSE:CTVA) with a Overweight and raises the price target from $58 to $63.

1 minute read

Keybanc Maintains Overweight on Corteva, Raises Price Target to $58

Today, 11:28 PM

Keybanc analyst Aleksey Yefremov maintains Corteva (NYSE:CTVA) with a Overweight and raises the price target from $55 to $58.

1 minute read

Corteva: Q4 Earnings Insights

Today, 11:28 PM

Corteva (NYSE:CTVA) reported its Q4 earnings results on Wednesday, February 2, 2022 at 05:00 PM. Here's what investors need to know about the announcement.